Drug Database: 10-1074

Pharmacology

Pharmacology

Mechanism of Action

Broadly neutralizing antibody (bNAb). 10-1074 is a recombinant human IgG1 lambda monoclonal antibody. It is a next-generation bNAb that targets the base of the V3 loop and surrounding glycans on the HIV envelope spike protein.^4,5

Second-generation HIV bNAbs are naturally occurring antibodies with potent neutralizing activity against a broad array of HIV strains. The utility of bNAbs is being researched for both HIV prevention and treatment/cure. By binding to sites on HIV envelope and through Fc receptor interactions, bNAbs can potentially 1) inhibit cell-free and cell-to-cell viral entry, 2) induce cellular phagocytosis and destruction by macrophages or antibody dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells, and 3) promote the maturation and activity of dendritic cells.^6–9 Because it is difficult to induce in vivo generation of bNAbs using conventional vaccination techniques, bNAbs may need to be given by passive transfer, whereby a bNAb is directly administered to an individual.^7,10

10-1074 and long-acting versions of 10-1074 (known as 10-1074-LS [zinlirvimab; GS-2872] and 10-1074-LS-J) are being developed for HIV prevention and/or as a possible component to HIV treatment or cure.^1,2

Half-life (T_½)

In a Phase 1 trial (NCT02511990) where 10-1074 was administered as a single intravenous (IV) infusion (3, 10, or 30 mg/kg) to adults with and without HIV, the estimated serum half-life of 10-1074 was found to be 12.8 days in participants with HIV and 24 days in participants without HIV.⁵

The half-life of modified long-acting 10-1074-LS was estimated in a preclinical study in uninfected macaques. Following a single IV infusion of 10-1074 LS (20 mg/kg), the median half-life was 3.8 weeks, representing a 3.8-fold increase compared to the half-life of unmodified 10-1074 administered in macaques.¹¹ 

Resistance

Treatment-emergent resistance to 10-1074 has been observed in clinical trials. In a Phase 1 dose-escalation study (NCT02511990), multiple 10-1074-resistant HIV variants were detected in participants following a single infusion of 10-1074. Resistance to 10-1074 arose from pre-existing virus and/or selection of new variants within weeks after 10-1074 infusion. Escape variants, however, were found to retain sensitivity to bNAbs that target non-overlapping sites on HIV-1 Env (3BNC117, VRC01, and PGDM1400).⁵

In a Phase 1b trial (NCT02825797) that evaluated 3BNC117 administered in combination with 10-1074, resistance to 10-1074 emerged as serum levels of 3BNC117 decreased (essentially resulting in 10-1074 monotherapy). Notably, however, no participants developed resistance to both antibodies during the trial.^12,13

Select Clinical Trials

Select Clinical Trials

Study Identifiers: Tatelo Study; NCT03707977

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase: 1/2
Status: This study has been completed.
Study Purpose: The purpose of this open-label study was to evaluate the efficacy of the investigational bNAbs VRC01LS and 10-1074 in maintaining HIV suppression in a cohort of children who had received early ART treatment.
Study Population:

• Participants were children who had initiated ART from less than 7 days of age and who continued ART for at least 96 weeks.
• Participants had HIV RNA <40 copies/mL for at least 24 weeks before study entry.^14,15

Selected Study Results: Results published in Sci Transl Med (2023) and presented at CROI 2022 showed that treatment with 10-1074 and VRC01LS was safe and effective. Among study participants who stopped ART, 44% maintained viral load levels less than 40 copies/mL through 24 weeks of bNAb-only treatment. Participants with a longer time on ART and bNAb overlap were more likely to succeed along with those who enrolled earlier in the study and had favorable pre-intervention clinical and reservoir characteristics.^15,16 
Additional Published Material: 

• CROI, 2020: Safety and pharmacokinetics of intravenous VRC01LS and 10-1074 in young children
• CROI, 2021: Safety and pharmacokinetics of VRC01LS and 10-1074 among children in Botswana

Study Identifier: NCT04357821

Sponsor: University of California, San Francisco
Phase: 1/2
Status: This study is ongoing, but not recruiting participants.
Study Purpose: The purpose of this open-label study is to evaluate whether a combination regimen can control viral load levels during an analytical treatment interruption of ART. The combination regimen includes (1) therapeutic HIV vaccines (Gag conserved element [CE]-targeted DNA+IL-12 prime/MVA boost vaccination), (2) bNAbs VRC07-523LS and 10-1074, and (3) the TLR9 agonist lefitolimod.
Study Population:

• Participants are adults with HIV who have been on a continuous ART regimen for at least 12 months. For at least 4 weeks before study entry, participants have been on a stable ART regimen that does not include an NNRTI.
• Participants have had undetectable HIV RNA in the past 24 months and have CD4 counts ≥500 cells/mm³ at screening.^17,18

Selected Study Results: Results presented at CROI 2023 indicated that most of the participants (seven out of 10) who received combination therapy had at least partial virologic control after ART interruption. The average time to viral rebound following ART interruption was 15 weeks.¹⁸

Study Identifiers: A5374; NCT06071767

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase: 1/2a
Status: This study is currently recruiting participants.
Study Purpose: The purpose of this study is the evaluate the safety and efficacy of a combination regimen in adults who initiated suppressive ART during acute HIV infection. The combination regimen contains (1) ChAdV- and MVA-vectored conserved mosaic T-cell vaccines, (2) the TLR7 agonist vesatolimod, and (3) two broadly neutralizing antibodies 3BNC117-LS (GS-5423) and 10-1074-LS (GS-2872).
Study Population:

• Participants are adults with HIV who initiated ART within 28 days of acute HIV diagnosis and who have not interrupted ART for more than 14 consecutive days since initiation of ART.
• Participants have been receiving ART with an INSTI-based regimen with two NRTIs or a dolutegravir/lamivudine regimen for at least 6 weeks prior to study entry.
• Participants have had HIV RNA <50 copies/mL since initial viral suppression on ART and for at least 1 year and within 60 days prior to study entry. 
• Participants have CD4 counts ≥500 cells/mm³ obtained within 60 days of study entry.¹⁹

Study Identifiers: TITAN; NCT03837756

Sponsor: University of Aarhus
Phase: 2a
Status: This study has been completed.
Study Purpose: The purpose of this study was to evaluate the safety of the TLR9 agonist lefitolimod administered with the bNAbs 3BNC117 and 10-1074 and to evaluate whether this combination could delay the time to viral rebound during an ATI of ART.
Study Population:

• Participants were adults with HIV who had been on ART for at least 18 months.
• Participants have had HIV RNA <50 copies/mL for at least 15 months and have CD4 counts >500 cells/mm³ at screening.
• Participants had HIV that was sensitive to 3BNC117 and 10-1074.²¹

Selected Study Results: Results published in Nature Medicine (2023) and presented at CROI 2023 showed that the groups receiving dual bNAb treatment had a significant delay in time to viral rebound during ART interruption, as compared to groups receiving placebos only or lefitolimod plus placebo. The addition of lefitolimod to dual bNAb treatment did not confer any additional effect on viral control compared to dual bNAb treatment alone.^21,22

Study Identifiers: RIO; NCT04319367

Sponsor: Imperial College London
Phase: 2
Status: This study is currently recruiting participants.
Study Purpose: The purpose of this study is to determine whether the combination of two long-acting bNAbs, 3BNC117-LS and 10-1074-LS, can prevent viral rebound during an ATI of ART.
Study Population:

• Participants are adults with HIV who had previously been diagnosed with primary HIV infection and who had started ART either within 6 months of the estimated time of primary HIV infection or during the early stage of infection.
• Participants have been receiving continuous suppressive ART for at least 1 year and are on an INSTI- or boosted PI-based regimen at the time of randomization.
• Participants have had undetectable HIV RNA for at least 1 year and have current CD4 counts >500 cells/mm³.
• Participants show no evidence of viral insensitivity to either 10-1074 or 3BNC117.^23,24

Study Identifiers: GS-US-536-5939; NCT05729568

Sponsor: Gilead Sciences
Phase: 2
Status: This study is ongoing, but not recruiting participants.
Study Purpose: The purpose of this open-label study is to evaluate the safety and efficacy of the bNAbs 3BNC117-LS (GS-5423) and 10-1074-LS (GS-2872) in combination with the capsid inhibitor lenacapavir as long-acting treatment.
Study Population:

• Participants are adults with HIV who have been receiving a stable oral ART regimen consisting of no more than two drug classes (with the exception of pharmacokinetic enhancers) for at least 1 year.
• Participants have had HIV RNA <50 copies/mL for at least 12 months prior to screening and at screening. 
• Participants have CD4 counts ≥200 cells/mm³ at screening.
• Participants have no previous resistance to their current ART regimen, except for isolated NRTI mutations.²⁵

Study Identifiers: RHIVIERA-02; NCT05300035

Sponsor: ANRS, Emerging Infectious Diseases
Phase: 2
Status: This study is currently recruiting participants.
Study Purpose: The purpose of this study is to evaluate the efficacy of the long-acting bNAbs 3BNC117-LS and 10-1074-LS in controlling viral load levels during an ATI of ART.
Study Population: Participants are adults with primary HIV infection who are initiating ART.²⁶

Study Identifiers: ACACIA Study; ACTG A5417; NCT06205602

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase: 2
Status: See the ClinicalTrials.gov record for this study’s status.
Study Purpose: The purpose of this study is to evaluate the safety of the long-acting bNAbs 3BNC117-LS and 10-1074-LS and determine whether the combination of the two bNAbs can prevent viral rebound during an ATI of ART.
Study Population: 

• Participants are treatment-naive adults with HIV in Sub-Saharan Africa.
• Participants have HIV RNA >1,000 copies/mL and CD4 counts >200 cells/mm3.²⁷

Additional studies evaluating 10-1074 for HIV treatment have been completed or are being conducted, including the following early-phase trials:

• NCT03526848: A Phase 1 study that evaluated whether 3BNC117 and 10-1074 could control viral load levels in adults with HIV during an ATI of ART. This study has been completed and results are available from Nature (2022).²⁸
• NCT04250636: A Phase 1 study that evaluated the safety, pharmacokinetics, and antiviral activity of single infusions of both 3BNC117-LS and 10-1074-LS in adults with HIV who were off ART. This study has been completed, and results are available from CROI 2022.²⁹
• NCT04811040: A Phase 1b study that evaluated the safety and efficacy of 3BNC117-LS (GS-5423) and 10-1074-LS (GS-2872) in combination with the capsid inhibitor lenacapavir in controlling viral load levels in virologically suppressed adults with HIV. This study has been completed, and results are available from The Lancet HIV (2024) and CROI 2024.³⁰
• BEAT-2 (NCT03588715): A Phase 1 study that evaluated whether peginterferon alfa-2b plus 3BNC117 and 10-1074 could control viral rebound and reduce the latent HIV reservoir in adults with HIV during an ATI of ART. This study has been completed, and primary outcome results are available from CROI 2023.^1,31
• ACTG A5386 (NCT04340596): A Phase 1 trial investigating the safety and efficacy of N-803 (an IL-15 superagonist) administered with and without the bNAbs VRC07-523LS and 10-1074 in controlling viral load during a treatment interruption of ART. This study is currently recruiting participants.³²
• MCA-1031 (ES38918) (NCT05245292): A Phase 1 trial evaluating the safety and antiviral activity of 3BNC117-LS and 10-1074-LS in combination with N-803 in virologically suppressed adults with HIV during an ATI of ART. This study is ongoing, but not recruiting participants.³³
• NCT05612178: A phase 1 study investigating the safety and efficacy of 3BCNC117-LS and 10-1074-LS on persistent viral reservoirs in people with HIV on suppressive ART. This study is currently recruiting participants.³⁴
• ACTG A5416 (NCT06031272): A Phase 1 study evaluating the safety and antiviral activity of 3BNC117-LS-J and 10-1074-LS-J in virologically suppressed adults with HIV undergoing an ATI of ART. This study is currently recruiting participants.³⁵ 

Adverse Events

Adverse Events

Tatelo Study (NCT03707977)

In this Phase 1/2 trial, 28 children received daily ART in combination with the bNAbs VRC01LS and 10-1074 administered every 4 weeks for at least 8 weeks (ART/bNAb overlap step). Twenty-five children completed the ART/bNAb overlap step and entered the bNAb-only step of the study, where ART was discontinued for up to 24 weeks. No infusion reactions were reported throughout the study. Five Grade 3 adverse events (AEs) occurred in three participants. One of the Grade 3 events (neutropenia) was considered possibly related to bNAb treatment. No Grade 4 AEs occurred, and there were no study drug discontinuations due to Grade 3 or 4 AEs.^14,15

TITAN (NCT03837756)

In this Phase 2a trial, participants were randomized to receive placebo/placebo (n=10), lefitolimod/placebo (n=10), placebo/bNAbs (n=11), or lefitolimod/bNAbs (n=12). Out of 253 reported AEs, 94 were considered unrelated to any investigational drug or placebo. Eighty-one AEs, most of which were mild in intensity, were related to lefitolimod. The most common lefitolimod-related AEs were injection site reactions (n = 39) and fatigue (n = 6). Fourteen AEs were related to bNAb therapy — 11 were mild, two were moderate, and one was severe. The severe bNAb-related AE was an infusion-related reaction to 3BNC117 that resolved with treatment. The most common AE related to bNAb therapy was fatigue (n = 5).²¹

Drug Interactions

Drug Interactions

Drug-drug interactions associated with 10-1074 are currently unknown.

References

References

1. Treatment Action Group website. Research toward a cure trials. Accessed October 23, 2024
2. Jefferys R. The HIV vaccines and passive immunization pipeline report 2024. Treatment Action Group Pipeline Report 2024. Accessed October 23, 2024
3. Gilead Sciences: press release, dated January 9, 2020. Gilead Sciences licenses portfolio of HIV antibodies from The Rockefeller University. Accessed October 23, 2024
4. Sharma VK, Misra B, McManus KT, et al. Characterization of co-formulated high-concentration broadly neutralizing anti-HIV-1 monoclonal antibodies for subcutaneous administration. Antibodies (Basel). 2020;9(3):36. doi:10.3390/antib9030036. Accessed October 23, 2024
5. Caskey M, Schoofs T, Gruell H, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185-191. doi:10.1038/nm.4268. Accessed October 23, 2024
6. Liu Y, Cao W, Sun M, Li T. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect. 9(1):194-206. doi:10.1080/22221751.2020.1713707. Accessed October 23, 2024
7. Halper-Stromberg A, Nussenzweig MC. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest. 126(2):415-423. Accessed October 23, 2024
8. Bruel T, Guivel-Benhassine F, Amraoui S, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016;7:10844. Accessed October 23, 2024
9. Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. Curr HIV/AIDS Rep. 2016;13:31-37. Accessed October 23, 2024
10. Caskey M, Klein F, Lorenzi JC, et al. 3BNC117 a broadly neutralizing antibody suppresses viremia in HIV-1-infected humans. Nature. 2015;522(7557):487-491. Accessed October 23, 2024
11. Gautam R, Nishimura Y, Gaughan N, et al. A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018;24(5):610-616. doi:10.1038/s41591-018-0001-2. Accessed October 23, 2024
12. Bar-On Y, Gruell H, Schoofs T, et al. Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24(11):1701-1707. doi:10.1038/s41591-018-0186-4. Accessed October 23, 2024
13. Mendoza P, Gruell H, Nogueira L, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479-484. doi:10.1038/s41586-018-0531-2. Accessed October 23, 2024
14. National Institute of Allergy and Infectious Diseases (NIAID). A clinical trial to evaluate the impact of broadly neutralizing antibodies VRC01LS and 10-1074 on maintenance of HIV suppression in a cohort of early-treated children in Botswana (dual bNAb treatment in children). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 12, 2018. NLM Identifier: NCT03707977. Accessed October 23, 2024
15. Shapiro RL, Ajibola G, Maswabi K, et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Science Translational Medicine. 2023;15(703):eadh0004. doi:10.1126/scitranslmed.adh0004. Accessed October 23, 2024
16. Shapiro RL, Maswabi K, Ajibola G, et al. Treatment with broadly neutralizing antibodies in children with HIV in Botswana (The Tatelo Study). Webcast presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16, 2022; Virtual. Accessed October 23, 2024
17. University of California, San Francisco. Combinatorial therapy with a therapeutic conserved element DNA vaccine, MVA vaccine boost, TLR9 agonist and broadly neutralizing antibodies: a proof-of-concept study aimed at inducing an HIV remission. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 18, 2020. NLM Identifier: NCT04357821. Accessed October 23, 2024
18. Peluso M, Deitchman A, Magombedze G, et al. Rebound dynamics following immunotherapy with an HIV vaccine, TLR-9 agonist, and broadly neutralizing antibodies. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 19-22, 2023; Seattle, WA. Poster 435. Accessed October 23, 2024
19. National Institute of Allergy and Infectious Diseases (NIAID). A Phase I/IIa randomized, placebo-controlled trial of conserved-mosaic T-cell vaccine in a regimen with vesatolimod and broadly neutralizing antibodies in adults initiated on suppressive antiretroviral therapy during acute HIV-1. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on September 5, 2023. NLM Identifier: NCT06071767. Accessed October 23, 2024
20. University of Aarhus. Combining a TLR9 agonist with broadly neutralizing antibodies for reservoir reduction and immunological control of HIV infection: an investigator-initiated randomized, placebo-controlled, Phase IIa trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 7, 2019. NLM Identifier: NCT03837756. Accessed October 23, 2024
21. Gunst JD, Højen JF, Pahus MH, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med. 2023;29(10):2547-2558. doi:10.1038/s41591-023-02547-6. Accessed October 23, 2024
22. Gunst JD, Reikvam DH, McMahon JH, et al. The impact of 3BNC117, 10-1074, and lefitolimod on HIV-1 persistence: the TITAN trial. Abstract presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 19-22, 2023; Seattle, WA. Abstract 136. Accessed October 23, 2024
23. Imperial College London. A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated primary HIV infection on viral control off ART. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 2, 2020. NLM Identifier: NCT04319367. Accessed October 23, 2024
24. Lee JM, Collins S, Babalis D, et al. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial. Trials. 23(1):263. doi:10.1186/s13063-022-06151-w. Accessed October 23, 2024
25. Gilead Sciences. A Phase 2 randomized, open-label study to evaluate the safety and efficacy of broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with the capsid inhibitor lenacapavir as long-acting treatment dosed every 6 months in virologically suppressed adults with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 6, 2023. NLM Identifier: NCT05729568. Accessed October 23, 2024
26. ANRS, Emerging Infectious Diseases. A randomised Phase II placebo-controlled trial of antiretroviral therapy (ART) plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact on post-treatment HIV control. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 3, 2022. NLM Identifier: NCT05300035. Accessed October 23, 2024
27. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. A randomized, double-blind, placebo-controlled study of the combination of two long-acting broadly neutralizing antibodies at ART initiation in adults living with HIV-1 in Sub-Saharan Africa: The ACACIA Study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 4, 2024. NLM Identifier: NCT06205602. Accessed October 23, 2024
28. Rockefeller University. An open label, randomized study of the safety and antiretroviral activity of 3BNC117 and 10-1074 in HIV-infected individuals on combination antiretroviral therapy and during analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 3, 2018. NLM Identifier: NCT03526848. Accessed October 23, 2024
29. Rockefeller University. An open label, single arm study of the safety, pharmacokinetics and antiretroviral activity of the combination of 3BNC117-LS and 10-1074-LS in viremic HIV-infected individuals. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 30, 2020. NLM Identifier: NCT04250636. Accessed October 23, 2024
30. Gilead Sciences. A Phase 1b randomized, blinded, proof-of-concept study to evaluate the safety and efficacy of broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination with capsid inhibitor lenacapavir (GS-6207) in virologically suppressed adults with HIV-1 infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 19, 2021. NLM Identifier: NCT04811040. Accessed October 23, 2024
31. Luis Montaner. Pilot study on innate activation and viral control in HIV-infected adults undergoing an analytical treatment interruption after administration of pegylated interferon alpha 2b with broadly HIV-1 neutralizing antibodies (3BNC117, 10-1074). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 30, 2018. NLM Identifier: NCT03588715. Accessed October 23, 2024
32. National Institute of Allergy and Infectious Diseases (NIAID). A Phase I clinical trial of the safety, tolerability, and efficacy of IL-15 superagonist (N-803) with and without combination broadly neutralizing antibodies to induce HIV-1 control during analytic treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 23, 2020. NLM Identifier: NCT04340596. Accessed October 23, 2024
33. Rockefeller University. An open label, single arm study of the safety and antiretroviral activity of two long-acting broadly neutralizing antibodies plus an IL-15 superagonist in ART-treated adults living with HIV during analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 8, 2022. NLM Identifier: NCT05245292. Accessed October 23, 2024
34. National Institute of Allergy and Infectious Diseases (NIAID). A randomized placebo-controlled study to evaluate the safety and effects of repeated doses of 3BNC117-LS and 10-1074-LS on persistent viral reservoirs in people living with HIV and on suppressive antiretroviral therapy. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 9, 2022. NLM Identifier: NCT05612178. Accessed October 23, 2024
35. AIDS Clinical Trials Group. A Phase I, randomized, placebo-controlled study of the safety, antiviral & immunomodulatory activity of broadly neutralizing antibodies 3BNC117-LS-J and 10-1074-LS-J in combination in ART-treated adults in sub-Saharan Africa living with HIV during a monitored analytical treatment interruption. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 14, 2023. NLM Identifier: NCT06031272. Accessed October 23, 2024

Last Reviewed: October 23, 2024